Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 2/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | PDE5A | O76074 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921528 | 1.00 | CCKBR (0.85) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL1921583 | 1.00 | CCKBR (0.85) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL4600163 | 1.00 | CCKBR (0.85) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL13402875 | 1.00 | CCKBR (0.85) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL17760646 | 1.00 | CCKBR (0.85) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL1520461 | 0.92 | CCKBR (1.00) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL13402890 | 0.92 | CCKBR (0.80) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL21309527 | 0.92 | CCKBR (0.83) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL28356816 | 0.92 | CCKBR (0.80) | CCKBRCYP2D6TSHRMAPK1PDE5A | |
| SCHEMBL18531899 | 0.92 | CCKBR (0.83) | CCKBRCYP2D6TSHRMAPK1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111675725-B | Tetrahydro-beta-carbaline dimer and preparation method and application thereof | 中国药科大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-111303148-B | 1-substituted beta-carboline derivatives and application thereof | 南京农业大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111675725-A | Tetrahydro-beta-carbaline dimer and preparation method and application thereof | 中国药科大学 | 2020-09-18 | — | — | CN | disclosed |
| CN-105037350-B | A kind of harmel alkaloid compound and its application in terms of peronophythora litchi is prevented and treated | 华南农业大学 | 2017-09-22 | — | — | CN | disclosed |
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| CN-104628722-B | A kind of banisterine amides compound and its preparation method and application | 华南农业大学 | 2016-06-22 | — | — | CN | disclosed |
| CN-105037350-A | Harmine compound and applications of harmine compound in prevention and control of peronophthora litchi chen disease | UNIV SOUTH CHINA AGRICULT | 2015-11-11 | — | — | CN | disclosed |
| US-9169247-B2 | Tetrahydro-beta-carboline derivatives, synthesis and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2015-10-27 | — | — | US | disclosed |
| CN-104628722-A | Harmaline amide compound as well as preparation method and application thereof | UNIV SOUTH CHINA AGRICULT | 2015-05-20 | — | — | CN | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| US-8546421-B1 | Oncogenic-RAS-signal dependent lethal compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546421-B1 | Oncogenic-RAS-signal dependent lethal compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120309781-A1 | TETRAHYDRO-beta-CARBOLINE DERIVATIVES, SYNTHESIS AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| WO-2008103470-A2 | ONCOGENIC-RAS-SIGNAL DEPENDENT LETHAL COMPOUNDS | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2004113336-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | CCKBR 981/4885CYP2D6 347/4885TSHR 1374/4885 |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | CCKBR 981/4885CYP2D6 347/4885TSHR 1374/4885 |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | HRAS, KRAS, NRAS | CCKBR 3754/4885CYP2D6 3927/4885TSHR 4164/4885 |
| US-20120309781-A1 | TETRAHYDRO-beta-CARBOLINE DERIVATIVES, SYNTHESIS AND USE THEREOF | PDE5A, PDE3A, PDE3B | CCKBR 2503/4885CYP2D6 100/4885TSHR 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.